/

DMAC

DiaMedica Therapeutics Inc.Pre-market

7.82−0.38 −4.63%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

8.21

Prev close

8.20

Day range

7.728.21

52-week range

5.2510.42

Volume

256.01K1.44×

Mkt cap

421.70M

P/E ttm

—

Fwd P/E

-9.68

EPS ttm

-0.7200

Div yield

0.00%

Earnings

Aug 10, 2026

From 52w high

−24.95%

Price Chart

Yahoo Finance · delayed

DMACOct 13, 2026O 8.21H 8.21L 7.72C 7.82−0.38 (−4.63%)Vol 256.00K

SMA 507.11
SMA 2007.09

1Y change +10.76% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

DMAC DiaMedica Therapeutics Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.81%
1 month: +20.87%
3 months: +5.25%
6 months: +19.57%
Year to date: −1.76%
1 year: +10.76%

Valuation & ownership

Market cap: 421.70M
Enterprise value: 378.38M
P/E (ttm): —
Forward P/E: -9.68
PEG ratio: —
Price / book: 11.00
Price / sales (ttm): —
EV / EBITDA: -9.66
EPS (ttm): -0.7200
EPS (forward): -0.8080
Beta (5y monthly): 0.91
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 53.93M
Float: 25.30M
Short % of float: 15.42%
Short ratio (days): 28.38
Held by insiders: 27.83%
Held by institutions: 40.92%
Avg volume (3m): 177.99K
50-day average: 7.09
200-day average: 7.09
52-week change: +10.76%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 53.1
vs 50-day SMA: +9.93%
vs 200-day SMA: +10.33%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.55%
Realised vol (20d, ann.): 50.1%
From 52-week high: −24.95%
From 52-week low: +49.09%

ANR

Analyst Consensus

4 analysts

Consensus

—

Mean target

15.50

+98.21% implied

Low 11.00Median 13.00High 25.00

Recommendation trend

Now5 / 0 / 0
1m ago5 / 0 / 0

Buy / hold / sell counts

DES

About DiaMedica Therapeutics Inc.

Yahoo Finance profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Sector: Healthcare
Industry: Biotechnology
Employees: 35
Headquarters: Minneapolis, MN, United States
Website: diamedica.com
Officers: Mr. Dietrich John Pauls MBA President, CEO & Director
Mr. Scott Kellen CPA CFO & Corporate Secretary
Dr. Julie Krop M.D. Chief Medical Officer
Dr. Ambarish Shah Ph.D. Chief Technology Officer

SEAS

Seasonality · DMAC

2012–2026 · monthly returns

Strongest month Jun +14.06%Weakest month Jul −8.27%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	1.0	-1.1	-14.8	-10.6	-1.0	17.5	-9.9	0.2	30.2	-5.4			−1.8%
2025	6.1	13.4	-42.0	9.5	-1.0	-5.1	8.2	35.3	20.3	2.8	22.2	-7.8	+46.6%
2024	-0.7	6.4	-7.7	-8.7	14.6	1.7	11.2	19.8	6.6	4.3	29.4	-4.0	+91.2%
2023	-14.6	28.1	-11.6	6.5	67.5	58.2	-21.8	-12.7	-12.5	-15.5	11.9	16.4	+79.7%
2022	-30.6	1.5	-4.9	-7.2	4.7	-16.9	-18.3	7.3	-29.9	-4.8	0.8	32.8	−57.6%
2021	-20.8	14.2	-0.2	2.7	-21.2	-39.9	-22.5	24.6	-6.7	-1.5	-5.3	-0.3	−63.2%
2020	-10.2	3.8	-38.1	41.1	17.0	50.0	-14.1	-20.2	-10.7	3.5	27.6	81.1	+109.1%
2019	34.0	-14.1	35.5	-27.1	-16.3	79.1	-24.8	-20.1	-30.5	38.6	9.8	54.0	+66.7%
2018	7.2	2.2	25.5	20.8	5.4	24.0	-15.5	-14.8	7.6	-21.6	-28.1	-38.5	−41.8%
2017	3.8	31.1	42.1	25.8	-21.2	-4.1	5.0	-2.0	44.2	-0.4	-7.9	-9.2	+127.7%
2016	14.9	1.6	19.7	25.2	-0.8	39.1	-17.2	3.8	0.0	0.0	-36.6	-12.2	+15.6%
2015	-2.0	65.3	-1.2	-10.0	13.9	0.0	-3.9	-30.2	54.0	3.1	-3.0	12.2	+90.0%
2014	5.5	-5.3	14.8	-21.8	-7.3	-10.3	15.7	-21.7	-32.7	-27.0	-77.3	-13.8	−93.5%
2013	-14.3	-1.7	-10.0	-0.1	5.7	7.1	-9.5	40.0	2.7	-33.0	-1.8	-9.4	−33.5%
2012									5.9	-6.8	-33.1	-2.3	−35.5%

INSD

Insider Activity · DMAC

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 9, 2026	Pauls Dietrich JohnChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	60.2K	—
Jan 1, 2026	Parsons James T CpaDirector	Stock Award(Grant) at price 8.42 per share.	10.1K	$85.00K
Jan 1, 2026	Giuffre Randall Michael M.D.Director	Stock Award(Grant) at price 8.42 per share.	6.2K	$51.99K
Jan 1, 2026	Semba Charles PaulingDirector	Stock Award(Grant) at price 8.42 per share.	3.4K	$28.25K
Nov 24, 2025	Stahlberg JanBeneficial Owner of more than 10% of a Class of Security	Purchase at price 6.52 - 8.57 per share.	1.06M	$7.63M
Nov 20, 2025	Parsons James T CpaDirector	Conversion of Exercise of derivative security at price 2.20 per share.	12K	$26.40K
Aug 26, 2025	Stahlberg JanBeneficial Owner of more than 10% of a Class of Security	Purchase at price 5.86 - 6.00 per share.	1.00M	$5.96M
Jul 22, 2025	Jacinto Richard IiBeneficial Owner of more than 10% of a Class of Security	Purchase at price 5.15 per share.	400K	$2.06M
Jul 22, 2025	Von Koch Nils ThomasBeneficial Owner of more than 10% of a Class of Security	Purchase at price 5.15 per share.	2.86M	$14.71M
Jul 22, 2025	Stahlberg JanBeneficial Owner of more than 10% of a Class of Security	Purchase at price 5.15 per share.	1.54M	$7.95M
Apr 6, 2025	Pilnik Richard DDirector	Conversion of Exercise of derivative security at price 2.11 per share.	24K	$50.64K
Feb 12, 2025	Giuffre Randall Michael M.D.Director	Conversion of Exercise of derivative security at price 2.11 - 3.65 per share.	17K	$43.57K
Jan 1, 2025	Kuntz Richard PDirector	Stock Award(Grant) at price 5.34 per share.	9.9K	$53.00K
Jan 1, 2025	Pilnik Richard DDirector	Stock Award(Grant) at price 5.34 per share.	10.4K	$55.50K
Jan 1, 2025	Parsons James T CpaDirector	Stock Award(Grant) at price 5.34 per share.	15.9K	$85.00K
Jan 1, 2025	Giuffre Randall Michael M.D.Director	Stock Award(Grant) at price 5.34 per share.	10.9K	$58.00K
Jan 1, 2025	Semba Charles PaulingDirector	Stock Award(Grant) at price 5.34 per share.	5.3K	$28.25K

DMAC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

DMAC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About DiaMedica Therapeutics Inc.

Seasonality · DMAC

Insider Activity · DMAC

Congress Trades · DMAC

Investors Holding DMAC

Investors Holding DMAC

Congress Trades · DMAC

Insider Activity · DMAC

Seasonality · DMAC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About DiaMedica Therapeutics Inc.

Financial Snapshot

Earnings & Dividends

News